n the wake of mounting anger over prescription drug costs, a new report by a Senate committee recommends several steps — such as accelerating regulatory review for generics and temporarily allowing imports — to blunt the financial impact that sudden price hikes are having on Americans.

The report from the Senate Special Committee on Aging follows a year-long probe into several well-publicized instances in which drug makers — notably, Valeant Pharmaceuticals and Turing Pharmaceuticals, which was run by Martin Shkreli — used controversial tactics to acquire older brand-name medicines and undermine competition after jacking up the prices to sky-high levels.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.